Menu
Itraconazole Capsule USP 100 mg is indicated for the treatment of the following fungal infections when thought likely to be susceptible:
Vulvovaginal candidiasis.
Pityriasis versicolor.
Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp. Microsporum spp. Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum.
Oral candidiasis.
Onychomycosis caused by dermatophytes and/or yeasts.
Treatment schedules in adults for each indication are as follows:
Indication Dose
Vulvovaginal candidiasis 200 mg twice daily for 1 day
Pityriasis versicolor 200 mg once daily for 7 days
Tinea corporis, tinea cruris 100 mg once daily for 15 days
Tinea pedis, tinea manuum 100 mg once daily for 30 days
Oral candidiasis 100 mg once daily for 14 days
Onychomycosis 200 mg once daily for 3 months
For skin infections, optimal clinical and mycological effects are reached at 1 – 4 weeks after cessation of treatment and for nail infections at 6 – 9 months after the cessation of treatment. This is because elimination of itraconazole from skin and nails is slower than from plasma.
In Acquired Immune Deficiency Syndrome and neutropenic patients: for the treatment of oral candidiasis 200 mg once daily for 14 days is recommended due to the impaired absorption of itraconazole in these patient groups.
The length of treatment for systemic fungal infections should be dictated by the mycological and clinical response to therapy.
Undesirable effects listed below have been reported in clinical trials with itraconazole capsules and/or from spontaneous reports from post-marketing experience for all itraconazole formulations.
In clinical trials involving 2104 itraconazole-treated patients in the treatment of dermatomycoses or onychomycosis, the most frequently reported adverse experiences were of gastrointestinal, dermatological, and hepatic origin. Abdominal pain, nausea, Rash
Cardiac effects
Itraconazole has been shown to have a negative inotropic effect and has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400 mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of itraconazole.
Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolisms of calcium channel blockers.
Hepatic effects
Very rare cases of serious hepatotoxicity, including some cases of fatal acute liver failure, have occurred with the use of itraconazole. Liver function monitoring should be considered in patients receiving itraconazole treatment. In patients with raised liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment should not be started unless the expected benefit exceeds the risk of hepatic injury.
Hearing loss
Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated. The hearing loss usually resolves when treatment is stopped.
Immunocompromised patients
In some immunosuppressed patients (e.g. in neutropenia, AIDS or after organ transplantation), the oral bioavailability of itraconazole may be decreased.
Patients with immediately life-threatening systemic fungal infections
Due to the pharmacokinetic properties, itraconazole capsules are not recommended for initiation of treatment in patients with immediately life-threatening systemic fungal infections.
Patients with AIDS
In patients with AIDS having received treatment for a systemic fungal infection such as sporotrichosis, blastomycosis, histoplasmosis or cryptococcosis (meningeal and non-meningeal) and who are considered at risk for relapse.
Store below 30oC and protect from light.
Keep the medicine out of reach of children.
10 × 10 Alu/PVC Blister.
Itraconazole Capsule USP 100 mg are available in an Alu/PVC blister of 10 capsules. Such 10 blisters in a unit carton with pack insert.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
We have below MOQ for:
We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.
A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.
Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.
For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.
For, Secondary packing we do use 300 to 400 GSM FFB Card board.
For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.
Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.
Conical Pharmaceuticals is a professionally managed and dynamic organization with decades of experience in the pharmaceutical field. With a desire of providing opportunities for a better life, we work very hard to bring quality drugs to our customers. We have instilled a level of trust and confidence amongst our clients by supplying the best quality products.